Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Michael Raab Biography and Net Worth

Director of Amicus Therapeutics

Michael G. Raab is President, Chief Executive Officer, Director of the Company. From 2002 to 2009, Mr. Raab was a partner at NEA, where he focused on investments in the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme’s diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol-Myers Corporation. Mr. Raab is currently a director of Amicus Therapeutics, Inc. (Nasdaq: FOLD). Mr. Raab currently serves as a member of the board of directors of the California Life Sciences Association, a non-profit trade association serving the life science industry in California, and as a member of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Mr. Raab received a B.A. from DePauw University.

What is Michael G. Raab's net worth?: The estimated net worth of Michael G. Raab is at least $11.27 million as of December 10th, 2024. Mr. Raab owns 1,150,385 shares of Amicus Therapeutics stock worth more than $11,273,773 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Raab may own. Learn More about Michael G. Raab's net worth.
How do I contact Michael G. Raab?: The corporate mailing address for Mr. Raab and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Michael G. Raab's contact information.
Has Michael G. Raab been buying or selling shares of Amicus Therapeutics?: Michael G. Raab has not been actively trading shares of Amicus Therapeutics during the last quarter. Most recently, Michael Raab sold 4,408 shares of the business's stock in a transaction on Friday, March 17th. The shares were sold at an average price of $11.33, for a transaction totalling $49,942.64. Following the completion of the sale, the director now directly owns 60,012 shares of the company's stock, valued at $679,935.96. Learn More on Michael G. Raab's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 316,307 shares worth more than $4,102,561.17. The most recent insider tranaction occured on December, 2nd when CEO Bradley L Campbell sold 7,500 shares worth more than $75,150.00. Insiders at Amicus Therapeutics own 2.2% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 12/2/2024.

Michael G. Raab Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/17/2023	Sell	4,408	$11.33	$49,942.64	60,012
6/1/2020	Sell	5,000	$12.65	$63,250.00	20,145
6/3/2019	Sell	5,000	$11.16	$55,800.00	13,895
4/16/2018	Sell	5,000	$14.41	$72,050.00	10,814
10/12/2017	Sell	10,000	$14.25	$142,500.00

Michael G. Raab Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $9.80

$9.60

$9.88

50 Day Range

MA: $10.48

$9.36

$12.01

2 Week Range

Now: $9.80

$9.02

$14.57

Volume

4,077,524 shs

Average Volume

2,724,375 shs

Market Capitalization

$2.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6